ProCE Banner Activity

Phase II KEYNOTE-942: DMFS With Adjuvant mRNA-4157 (V940) + Pembrolizumab vs Pembrolizumab in Resected High-Risk Melanoma

Conference Coverage

In patients with resected melanoma at high risk of recurrence, the addition of the individualized neoantigen therapy mRNA-4157 (V940) to adjuvant pembrolizumab showed clinically significant improvements in RFS and DMFS after a median follow-up of 2 years.

Released: June 08, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Merck Sharp & Dohme Corp. and Regeneron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc